替罗非班或阿加曲班联合溶栓未改善结局且死亡率升高
MOST试验的预设亚组分析纳入260例接受IVT-O的急性缺血性卒中患者,随机接受阿加曲班、依替巴肽或安慰剂。结果显示两种药物均未改善90天效用加权mRS,且死亡率显著高于安慰剂。
要点
- 阿加曲班或依替巴肽联合溶栓未改善90天功能结局
- 两种药物死亡率均显著高于安慰剂组
- 症状性出血风险无显著增加
核心结论
- 在发病3小时内接受IVT的AIS患者中,阿加曲班或依替巴肽联合治疗未改善结局,但死亡率增加。
研究设计与样本
- MOST试验为3臂、适应性、单盲、随机对照III期临床试验,在美国57个中心开展。
- 本分析为预设次要分析,纳入IVT-O队列260例,采用贝叶斯正态动态线性模型。
- 随机分组为阿加曲班(28例)、依替巴肽(114例)或安慰剂(118例)。
主要发现
- 阿加曲班、依替巴肽优于安慰剂的概率分别仅1%和2.5%(主要结局)。
- 90天uwmRS均值(SD):阿加曲班5.5(3.6)、依替巴肽6.6(3.2)、安慰剂7.4(2.6)。
- 症状性出血风险差:阿加曲班vs安慰剂-0.8%(p=0.82),依替巴肽vs安慰剂1.8%(p=0.36)。
- 死亡率:安慰剂3.4%,阿加曲班14.3%(p=0.03),依替巴肽11.4%(p=0.02)。
- 无任何亚组显示获益。
关键数值与推荐
- 主要终点为90天效用加权改良Rankin量表评分(uwmRS,0最差,10最佳)。
- 阿加曲班剂量:100 μg/kg弹丸注射,随后3 μg/kg/min输注12小时。
- 依替巴肽剂量:135 μg/kg弹丸注射,随后0.75 μg/kg/min输注2小时。
- 纳入标准:发病3小时内接受静脉阿替普酶或替奈普酶的AIS患者。
临床怎么用
- 不推荐在IVT-O基础上常规加用阿加曲班或依替巴肽。
- 对于接受IVT的AIS患者,加用上述药物可能增加死亡风险。
局限性
- 阿加曲班组样本量较小。
- 研究因无效而提前终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: IV thrombolysis only (IVT-O) is the primary reperfusion therapy for most stroke patients. At least 50% of IVT-O patients remain disabled. We assessed 2 therapies added to IVT-O aimed at increasing clot lysis or preventing arterial reocclusion. METHODS: This 3-arm, adaptive, single-blinded, randomized controlled phase III clinical trial was conducted at 57 US sites. Patients with acute ischemic stroke (AIS) within 3 hours of onset receiving IV tissue plasminogen activator or tenecteplase were randomized to argatroban (100 μg/kg bolus and 12-hour infusion at 3 μg/kg/min), eptifibatide (135 μg/kg bolus and 2-hour infusion at 0.75 μg/kg/min), or placebo (bolus and 12-hour infusion). The primary end point was utility-weighted 90-day modified Rankin Scale score (uwmRS score; worst = 0, best = 10). This prespecified secondary analysis was conducted on the intent-to-treat population in the IVT-O cohort using a Bayesian normal dynamic linear model. RESULTS: Of 514 patients enrolled into Multi-arm Optimization of Stroke Thrombolysis (MOST) before the study was stopped for futility, 260 were in the IVT-O cohort (118 treated with placebo, 114 with eptifibatide, and 28 with argatroban; mean age 66 years, 46.9% female). Baseline variables were similar across groups (median NIH Stroke Scale score 8, mean time from symptom onset to IVT 105 minutes, mean time from IVT bolus to study drug start 62 minutes). A clot was visible in 30.8% of patients. There was only a 1% or 2.5% chance that argatroban or eptifibatide, respectively, was superior to placebo for the primary outcome (mean uwmRS scores [SD] of 5.5 [3.6], 6.6 [3.2], and 7.4 [2.6] for argatroban, eptifibatide, and placebo, respectively). No secondary outcomes favored either treatment group. The risk difference for symptomatic hemorrhage between the argatroban and eptifibatide arms vs placebo was -0.8% (p = 0.82) and 1.8% (p = 0.36). Mortality was 3.4% with placebo, 14.3% for argatroban (p = 0.03), and 11.4% for eptifibatide (p = 0.02). There was no benefit in any subgroup. DISCUSSION: Outcomes in patients treated with IVT-O were not improved by adding either argatroban or eptifibatide. Increased bleeding was not observed, but mortality was higher in both investigational arms. Limitations included small sample size in the argatroban subgroup. TRIAL REGISTRATION INFORMATION: This study was registered on ClinicalTrials.gov (registration number: NCT03735979) on November 8, 2018. The first patient was enrolled on October 15, 2019. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that in patients with AIS treated with IVT within 3 hours of onset, argatroban or eptifibatide does not improve outcomes vs thrombolysis alone but does increase mortality.
引用
- Roy A, Elm J, Ingles JR, et al. Thrombolysis Alone vs With Argatroban or Eptifibatide: A Prespecified Subgroup Analysis of the MOST Trial. Neurology. 2025. PMID: 41071964. doi:10.1212/WNL.0000000000214228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。